Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-GRIP B PET Imaging in NHL Patients Receiving CD19 CAR-T Therapy
NCT06522932Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 64Cu-GRIP B in non-Hodgkin lymphoma (NHL) (2 cohorts). Primary endpoint: Proportion of positive tumors at the post-CAR-T scan at 32 days. Started Oct 2024; status: recruiting.
02
Drugs
64Cu-GRIP B
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06522932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522932.